Literature DB >> 28032311

Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients.

Levente Kuthi1, Alex Jenei2, Adrienn Hajdu2, István Németh3, Zoltán Varga4, Zoltán Bajory5, László Pajor5, Béla Iványi2.   

Abstract

The morphotype and grade of renal cell carcinoma (RCC) in 928 nephrectomies were reclassified according to the 2016 WHO classification in order to analyze the distribution and outcomes of RCC subtypes in Hungary, to assess whether microscopic tumor necrosis is an independent prognostic factor in clear cell RCC, and to study whether a two-tiered grading (low/high) for clear cell and papillary RCC provides similar prognostic information to that of the four-tiered ISUP grading system. 83.4% of the cohort were clear cell, 6.9% papillary, 4.5% chromophobe, 2.3% unclassified, 1.1% Xp11 translocation, 1.1% clear cell papillary, 0.3% collecting duct and 0.1% mucinous tubular and spindle cell RCCs. RCC occurred in 16 patients with end-stage kidney disease and none of them displayed features of acquired cystic kidney disease-associated RCC. The 5-year survival rates were as follows: chromophobe 100%, clear cell papillary 100%, clear cell low-grade 96%, papillary type 1 92%, clear cell high-grade 63%, papillary type 2 65%, unclassified 46%, Xp11 translocation 20%, and collecting duct 0%. The 5-year survival rates in low-grade and high-grade papillary RCC were 95% and 59%, respectively. In clear cell RCC, only the grade, the stage and the positive surgical margin proved to be independent prognostic factors statistically. Overall, papillary RCC occurred relatively infrequently; microscopic tumor necrosis in clear cell RCC did not predict the outcome independently of the tumor grading; and the assignment of clear cell and papillary RCCs into low-grade or high-grade tumors was in terms of survival no worse than the ISUP grading.

Entities:  

Keywords:  ISUP grading; Microscopic tumor necrosis; Prognostic factors; Renal cell carcinoma; Survival rates

Mesh:

Year:  2016        PMID: 28032311     DOI: 10.1007/s12253-016-0179-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  38 in total

1.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

Authors:  John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.

Authors:  Bradley C Leibovich; Christine M Lohse; Paul L Crispen; Stephen A Boorjian; R Houston Thompson; Michael L Blute; John C Cheville
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

3.  Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.

Authors:  Satish K Tickoo; Mariza N dePeralta-Venturina; Lara R Harik; Heath D Worcester; Mohamed E Salama; Andrew N Young; Holger Moch; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

4.  Clear cell renal cell tumors: Not all that is "clear" is cancer.

Authors:  Sean R Williamson; Liang Cheng
Journal:  Urol Oncol       Date:  2016-03-14       Impact factor: 3.498

Review 5.  Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.

Authors:  Phillip M Pierorazio; Michael H Johnson; Hiten D Patel; Stephen M Sozio; Ritu Sharma; Emmanuel Iyoha; Eric B Bass; Mohamad E Allaf
Journal:  J Urol       Date:  2016-05-06       Impact factor: 7.450

6.  Renal cell carcinoma stage migration in a single European centre over 25 years: effects on 5- and 10-year metastasis-free survival.

Authors:  Martin Pichler; Georg C Hutterer; Thomas F Chromecki; Johanna Jesche; Karin Kampel-Kettner; Karl Pummer; Richard Zigeuner
Journal:  Int Urol Nephrol       Date:  2012-03-29       Impact factor: 2.370

7.  A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis.

Authors:  Brett Delahunt; Jesse K McKenney; Christine M Lohse; Bradley C Leibovich; Robert Houston Thompson; Stephen A Boorjian; John C Cheville
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

8.  Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis.

Authors:  Sebastian Frees; Mohammed M Kamal; Lisa Knoechlein; Robert Bell; Christopher Ziesel; Andreas Neisius; Christian Thomas; Walburgis Brenner; Wolfgang Jäger; Joachim W Thüroff; Frederik C Roos
Journal:  Urology       Date:  2016-06-01       Impact factor: 2.649

9.  The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.

Authors:  Sandra Steffens; Martin Janssen; Frederik C Roos; Frank Becker; Julie Steinestel; Mahmoud Abbas; Konrad Steinestel; Gerd Wegener; Stefan Siemer; Joachim W Thüroff; Rainer Hofmann; Michael Stöckle; Mark Schrader; Arndt Hartmann; Andrea Hasenfus; Markus A Kuczyk; Kerstin Junker; Andres J Schrader
Journal:  Hum Pathol       Date:  2014-08-23       Impact factor: 3.466

10.  Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.

Authors:  Joshua I Warrick; Alex Tsodikov; Lakshmi P Kunju; Arul M Chinnaiyan; Ganesh S Palapattu; Todd M Morgan; Ajjai Alva; Scott Tomlins; Angela Wu; Jeffrey S Montgomery; Khaled S Hafez; J Stuart Wolf; Alon Z Weizer; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-02-20       Impact factor: 3.466

View more
  24 in total

1.  Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI.

Authors:  Yulian Mytsyk; Ihor Dutka; Borys Yuriy; Iryna Maksymovych; Martin Caprnda; Katarina Gazdikova; Luis Rodrigo; Peter Kruzliak; Polina Illjuk; Ammad Ahmad Farooqi
Journal:  Int Urol Nephrol       Date:  2017-12-11       Impact factor: 2.370

Review 2.  Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment.

Authors:  Stuart G Silverman; Ivan Pedrosa; James H Ellis; Nicole M Hindman; Nicola Schieda; Andrew D Smith; Erick M Remer; Atul B Shinagare; Nicole E Curci; Steven S Raman; Shane A Wells; Samuel D Kaffenberger; Zhen J Wang; Hersh Chandarana; Matthew S Davenport
Journal:  Radiology       Date:  2019-06-18       Impact factor: 11.105

3.  Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.

Authors:  Sangjun Yoo; Dalsan You; In Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-27       Impact factor: 4.553

4.  Impact of Renal Cell Carcinoma Histological Variants on Recurrence After Partial Nephrectomy: A Multi-Institutional, Prospective Study (UROCCR Study 82).

Authors:  Thomas Tabourin; Ugo Pinar; Jerome Parra; Christophe Vaessen; Charles-Karim Bensalah; Francois Audenet; Pierre Bigot; Cecile Champy; Jonathan Olivier; Franck Bruyere; Nicolas Doumerc; Philippe Paparel; Bastien Parier; Francois-Xavier Nouhaud; Xavier Durand; Herve Lang; Nicolas Branger; Jean-Alexandre Long; Matthieu Durand; Thibaut Waeckel; Thomas Charles; Olivier Cussenot; Evanguelos Xylinas; Romain Boissier; Ricky Tambwe; Jean-Jacques Patard; Jean-Christophe Bernhard; Morgan Roupret
Journal:  Ann Surg Oncol       Date:  2022-07-03       Impact factor: 4.339

5.  MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.

Authors:  Yulian Mytsyk; Victor Dosenko; Yuriy Borys; Askold Kucher; Katarina Gazdikova; Dietrich Busselberg; Martin Caprnda; Peter Kruzliak; Ammad Ahmad Farooqi; Manyuk Lubov
Journal:  Int Urol Nephrol       Date:  2018-03-16       Impact factor: 2.370

Review 6.  Is percutaneous image-guided renal tumour ablation ready for prime time?

Authors:  Roberto Luigi Cazzato; Julien Garnon; Pierre De Marini; Pierre Auloge; Guillaume Koch; Danoob Dalili; Xavier Buy; Jean Palussiere; Pramod Prabhakar Rao; Thibault Tricard; Hervé Lang; Afshin Gangi
Journal:  Br J Radiol       Date:  2020-06-22       Impact factor: 3.039

7.  Single-cell genetic analysis validates cytopathological identification of circulating cancer cells in patients with clear cell renal cell carcinoma.

Authors:  Lucile Broncy; Basma Ben Njima; Arnaud Méjean; Christophe Béroud; Khaled Ben Romdhane; Marius Ilie; Veronique Hofman; Jane Muret; Paul Hofman; Habiba Chaabouni Bouhamed; And Patrizia Paterlini-Bréchot
Journal:  Oncotarget       Date:  2018-04-13

Review 8.  Circulating Tumor Cells for the Management of Renal Cell Carcinoma.

Authors:  Lucile Broncy; Patrizia Paterlini-Bréchot
Journal:  Diagnostics (Basel)       Date:  2018-09-03

9.  Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Authors:  Vadim S Koshkin; Pedro C Barata; Tian Zhang; Daniel J George; Michael B Atkins; William J Kelly; Nicholas J Vogelzang; Sumanta K Pal; JoAnn Hsu; Leonard J Appleman; Moshe C Ornstein; Timothy Gilligan; Petros Grivas; Jorge A Garcia; Brian I Rini
Journal:  J Immunother Cancer       Date:  2018-01-29       Impact factor: 13.751

10.  Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma.

Authors:  Levente Kuthi; Áron Somorácz; Tamás Micsik; Alex Jenei; Adrienn Hajdu; István Sejben; Dániel Imre; Boglárka Pósfai; Katalin Kóczián; Dávid Semjén; Zoltán Bajory; Janina Kulka; Béla Iványi
Journal:  Pathol Oncol Res       Date:  2020-01-18       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.